Treatment response, GVHD onset and overall survival were calculated from the first day of 5-Azacytidine treatment to the respective event. Death from whatever cause was counted as an event in case ...

5-azacytidine (5-aza), a DNA-methyltransferase inhibitor, was approved for treatment of advanced MDS. First, the Cancer and Leukemia Group B trial has shown some benefit of 5-aza in comparison with ...

PURPOSE: The impact of azacytidine (Aza C) on the quality of life of 191 patients with myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221). PATIENTS AND ...

The scientists show that the gene can be reactivated by treatment with an existing drug, 5-azacytidine. The results suggest that 5-azacytidine may function as targeted therapy for ALL in children.

Treatment with ruxolitinib plus azacytidine yielded encouraging spleen response rates and improvement in bone marrow fibrosis among patients with myelofibrosis, according an open-label ...

Azacytidine, Decitabine, Venetoclax combo-regimens) or intensive reinduction (high and intermediate dose of Cytarabine regimens) in the 2 nd, 3 rd, or 4 th salvage of AML and the 1 st interim ...

The recent arrival of the immune-checkpoint–inhibitor drugs — first applied to melanoma and more recently tested as a treatment for different solid tumors and hematologic cancers — has ...

A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic syndromes (MDS), with promising results. Cancer cells, particularly ...

The combination regimen delivered better overall survival and response rates among patients with myelodysplastic syndromes (MDS). Although hypomethylating agents (HMAs) such as 5-azacytidine (AZA ...

Combining the anticancer drugs azacytidine and retinoic acid significantly increased the amount of active NR2F1 in tumor cells. These patterns were found in mouse models of several cancers ...

especially when paired with azacytidine. The early findings were presented today at the 61 st American Society of Hematology (ASH) meeting in Orlando, Florida. The annual conference is attended by ...